drugset / Trial / NCT03790709
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Phase 2/3
Completed
509 enrolled
Anavex Life Sciences Corp.
Anavex Australia Pty Ltd. · collabAnavex Canada Ltd. · collabAnavex Germany GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.
Timeline
- Start
- 2018-07-03
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blarcamesine | Small molecule | — | Oral |